Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

被引：18

作者：

Pabel, Steffen ^{[1
]}

Hamdani, Nazha ^{[2
,3
]}

Singh, Jagdeep ^{[4
]}

Sossalla, Samuel ^{[1
,5
]}

机构：

[1] Univ Hosp Regensburg, Dept Internal Med 2, Regensburg, Germany

[2] Ruhr Univ Bochum, Dept Mol & Expt Cardiol, Inst Forsch & Lehre IFL, Bochum, Germany

[3] Ruhr Univ Bochum, St Josef Hosp, Dept Cardiol, Bochum, Germany

[4] Royal Infirm Edinburgh NHS Trust, Heart Ctr, Edinburgh, Midlothian, Scotland

[5] Georg August Univ Gottingen, Clin Cardiol & Pneumol, DZHK German Ctr Cardiovasc Res, Partner Site Gottingen, Gottingen, Germany

来源：

FRONTIERS IN PHYSIOLOGY | 2021年 / 12卷

关键词：

heart failure; HFpEF-heart failure with preserved ejection fraction; SGLT2; inhibitors; diastolic function; inflammation; oxidative stress; LATE SODIUM CURRENT; DIASTOLIC DYSFUNCTION; OXIDATIVE STRESS; NA+/H+ EXCHANGER; BLOOD-PRESSURE; KINASE-II; EMPAGLIFLOZIN; DAPAGLIFLOZIN; TITIN; INFLAMMATION;

D O I：

10.3389/fphys.2021.752370

中图分类号：

Q4 [生理学];

学科分类号：

071003 ;

摘要：

Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF patients. SGLT2i have already been shown to mitigate comorbidities associated with HFpEF such as type 2 diabetes and chronic renal disease, however, more recently there has been evidence that they may also directly improve diastolic function. In this article, we discuss some potential beneficial mechanisms of SGLT2i in the pathophysiology of HFpEF with focus on contractile function.

引用

页数：11

共 95 条

[1] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[3] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Khan, Muhammad Shahzeb ;

Marx, Nikolaus ;

Lam, Carolyn S. P. ;

Schnaidt, Sven ;

Ofstad, Anne Pernille ;

Brueckmann, Martina ;

Jamal, Waheed ;

Bocchi, Edimar A. ;

Ponikowski, Piotr ;

Perrone, Sergio, V ;

Januzzi, James L. ;

Verma, Subodh ;

Boehm, Michael ;

Ferreira, Joao Pedro ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

CIRCULATION, 2021, 143 (04) :337-349

[4] Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis [J].

Arnott, Clare ;

Li, Qiang ;

Kang, Amy ;

Neuen, Brendon L. ;

Bompoint, Severine ;

Lam, Carolyn S. P. ;

Rodgers, Anthony ;

Mahaffey, Kenneth W. ;

Cannon, Christopher P. ;

Perkovic, Vlado ;

Jardine, Meg J. ;

Neal, Bruce .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03)

[5]

McDonagh Theresa A, 2022, Rev Esp Cardiol (Engl Ed), V75, P523, DOI [10.1002/ejhf.2333, 10.1093/eurheartj/ehab368, 10.1016/j.rec.2022.05.005]

[6] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

[7] Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes [J].

Benham, Jamie L. ;

Booth, Jane E. ;

Sigal, Ronald J. ;

Daskalopoulou, Stella S. ;

Leung, Alexander A. ;

Rabi, Doreen M. .

IJC HEART & VASCULATURE, 2021, 33

[8] Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction [J].

Berg, David D. ;

Jhund, Pardeep S. ;

Docherty, Kieran F. ;

Murphy, Sabina A. ;

Verma, Subodh ;

Inzucchi, Silvio E. ;

Kober, Lars ;

Kosiborod, Mikhail N. ;

Langkilde, Anna Maria ;

Martinez, Felipe A. ;

Bengtsson, Olof ;

Ponikowski, Piotr ;

Sjostrand, Mikaela ;

Solomon, Scott D. ;

McMurray, John J. V. ;

Sabatine, Marc S. .

JAMA CARDIOLOGY, 2021, 6 (05) :499-507

[9] Cardiac excitation-contraction coupling [J].

Bers, DM .

NATURE, 2002, 415 (6868) :198-205

[10] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Steg, P. Gabriel ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Voors, Adriaan A. ;

Metra, Marco ;

Lund, Lars H. ;

Komajda, Michel ;

Testani, Jeffrey M. ;

Wilcox, Christopher S. ;

Ponikowski, Piotr ;

Lopes, Renato D. ;

Verma, Subodh ;

Lapuerta, Pablo ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :117-128

← 1 2 3 4 5 6 7 8 9 10 →